Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer

NCT00556023 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00556023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00556023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2008
Completion date
August 31, 2011
Enrollment
37 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer